Bowker et al followed 10,309 cases of tumor complicated with Type-2 diabetes for 5.5 years on average, finding fatality rates among patients taking Metformin, sulfonylureas and insulin to be 3.5%, 4.9% and 5.8%, respectively. This evidence concerns the gene INS and neoplasm.